Herpes Zoster Vaccination Rates in Hematological and Oncological Patients—Stock Taking 2 Years after Market Approval

Background: Vaccinations have the potential to significantly lower the burden of disease for many major infections in the high-risk population of hematological and oncological patients. In this regard Shingrix(®), an inactivated Varicella Zoster Virus vaccine, received market approval in the Europea...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiderlen, Til Ramón, Trostdorf, Katrin, Delmastro, Nicola, Salomon, Arne, de Wit, Maike, Reinwald, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408327/
https://www.ncbi.nlm.nih.gov/pubmed/36011181
http://dx.doi.org/10.3390/healthcare10081524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408327/
https://www.ncbi.nlm.nih.gov/pubmed/36011181
http://dx.doi.org/10.3390/healthcare10081524

Ejemplares similares